Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Dynulta Tablet
Manufacturer/Marketed By : EMCURE PHARMACEUTICALS LTD
$3.38 $2.71
Dynulta Tablet contains the active component sucroferric oxyhydroxide. It is classified as a phosphate binder. This medication treats hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis....
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
SUCROFERRIC OXYHYDROXIDE
Active Pharmaceutical Ingredient
Dynulta Tablet
3,38$
2,71$
Dynulta Tablet contains the active component sucroferric oxyhydroxide. It is classified as a phosphate binder. This medication treats hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Hyperphosphatemia is characterized by abnormally high levels of phosphate in the blood, a common complication of CKD. This medicine contains iron, which can benefit individuals with CKD who often experience iron deficiency anemia. Providing iron and phosphate binding helps address iron deficiency and support red blood cell production. You should not take Dynulta Tablet if you are allergic to it or its components. Allergic reactions can range from mild to severe and may include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Patients with iron overload disorders, such as hemochromatosis (iron overload disorder), or those receiving high-dose intravenous iron therapy should use Dynulta Tablet cautiously. The use of this medicine in pediatric patients has not been extensively studied, and its safety and effectiveness in this population have yet to be established.
Active Pharmaceutical Ingredient
Uses
• Treatment of high phosphate levels in the blood
Benefits
Dynulta Tablet is a medication that effectively lowers elevated phosphate levels in the blood, primarily in patients with chronic kidney disease (CKD) who are on dialysis. By binding to dietary phosphate in the gastrointestinal tract, this medication prevents its absorption into the bloodstream, thereby reducing the overall phosphate burden. This helps to manage hyperphosphatemia, a common complication of CKD, and minimize associated risks such as bone disease and cardiovascular complications.
Side Effects
Dynulta tablets cause some side effects like all medications, although not everyone will experience them.
Most Common Side Effects
• Diarrhea
• Discolored feces (usually dark or black)
• Constipation
• Nausea
• Vomiting
• Stomach pain or discomfort
• Indigestion or heartburn
Common Side Effects
• Allergic reaction
• Breathlessness
• Black stools
How To Use
To use Dynulta Tablet, follow the instructions provided by your healthcare professional or the guidelines on the medication packaging. Typically, this medication is taken orally as chewable tablets with meals or shortly after eating. The dosage and frequency of administration will depend on your specific medical condition and individual needs. It is important to chew the tablets thoroughly before swallowing. You may consult your healthcare provider for alternative administration options if you have difficulty chewing.
Safety Advice
• Breast Feeding: The safety of Dynulta Tablet during breastfeeding has not been well studied, and there is limited information on its excretion into human breast milk. Therefore, caution is advised when considering the use of breastfeeding.
• Alcohol: Excessive alcohol consumption can negatively affect your health, especially if you have underlying liver disease or other medical conditions. Alcohol can also contribute to dehydration, which may affect the management of certain medical conditions.
• Liver: The safety of Dynulta Tablet in individuals with liver disease has not been extensively studied. If you have liver disease or concerns about the safety of your liver, it is important to discuss these concerns with your healthcare provider.
• Lungs: Dynulta Tablet is not known to have specific safety concerns related to the lungs. If you have a pre-existing lung condition or are concerned about the safety of this medication in relation to your lungs, it is important to discuss your concerns with your healthcare provider.
• Driving: Dynulta Tablets can cause side effects that may impair your ability to drive or operate machinery safely. Common side effects are drowsiness and dizziness. These effects can affect your coordination, reaction time, and judgment, making driving unsafe or performing tasks requiring alertness.
• Pregnancy: The safety of Dynulta Tablet during pregnancy has not been well established, and there is limited clinical data regarding its use in pregnant women. Therefore, caution is advised when considering the use of this medication during pregnancy.
Disclaimer
Sidmex Inovia s'efforce de fournir des informations exactes et fiables. Cependant, l'ensemble du contenu de ce site web, y compris les descriptions et compositions des produits, est fourni à titre informatif uniquement et ne saurait se substituer à un avis, un diagnostic ou un traitement médical professionnel.
Il est conseillé aux utilisateurs de consulter un professionnel de santé qualifié avant toute décision médicale. Les informations fournies ne doivent pas être utilisées pour l'autodiagnostic ou l'automédication.
Tous les produits présentés sont exclusivement destinés aux professionnels (B2B) et aux demandes de renseignements en gros. Sidmex Inovia ne promeut pas la consommation directe par les particuliers et vise à soutenir, et non à remplacer, la relation entre le professionnel de santé et le patient.
Les noms de produits, marques et logos appartiennent à leurs propriétaires respectifs et leur utilisation n'implique aucune affiliation ni aucun parrainage. Sidmex Inovia décline toute responsabilité quant aux conséquences découlant de l'utilisation des informations fournies sur ce site web.